KD Logo

Oppenheimer analysts initates an Outperform rating for Corvus Pharmaceuticals Inc (CRVS)

Corvus Pharmaceuticals Inc’s filing revealed that its insider Jones William Benton acquired Company’s shares for reported $34624.0 on May 06 ’24. In the deal valued at $1.73 per share,20,000 shares were bought. As a result of this transaction, Jones William Benton now holds 153,773 shares worth roughly $0.89 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, MILLER RICHARD A MD bought 577,634 shares, generating $1,000,000 in total proceeds. Upon buying the shares at $1.73, the President and CEO now owns 577,634 shares.

Oppenheimer initiated its Corvus Pharmaceuticals Inc [CRVS] rating to an Outperform in a research note published on August 18, 2023; the price target was $7. Cantor Fitzgerald began covering CRVS with “an Overweight” recommendation on May 27, 2021. Mizuho revised its rating on February 10, 2021. It rated CRVS as “a Neutral” which previously was an “a Buy”.

Price Performance Review of CRVS

On Monday, Corvus Pharmaceuticals Inc [NASDAQ:CRVS] saw its stock jump 13.33% to $5.78. Over the last five days, the stock has gained 42.01%. Corvus Pharmaceuticals Inc shares have risen nearly 228.41% since the year began. Nevertheless, the stocks have risen 268.15% over the past one year. While a 52-week high of $5.22 was reached on 09/16/24, a 52-week low of $1.05 was recorded on 04/18/24. SMA at 50 days reached $3.37, while 200 days put it at $2.28.

Levels Of Support And Resistance For CRVS Stock

The 24-hour chart illustrates a support level at 5.30, which if violated will result in even more drops to 4.83. On the upside, there is a resistance level at 6.20. A further resistance level may holdings at 6.63. The Relative Strength Index (RSI) on the 14-day chart is 79.19, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.89, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 16.44%. Stochastics %K at 90.07% indicates the stock is a selling.

How much short interest is there in Corvus Pharmaceuticals Inc?

A steep rise in short interest was recorded in Corvus Pharmaceuticals Inc stocks on 2024-08-30, growing by 0.29 million shares to a total of 1.43 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-31 was 1.15 million shares. There was a rise of 19.97%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on September 12, 2019 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating .

Most Popular